Speculation over a return for Vioxx

Share this article:
The FDA's decision to allow Pfizer's Celebrex to remain on the market yesterday has led to speculation by some that Merck's Vioxx could also return, should the company seek its re-introduction.
A report published today on the business Web site Marketwatch.com said some investors are hoping Vioxx may make a comeback. In the report, Merck said it looked forward to discussions with the FDA over Vioxx but would not confirm whether negotiations with the agency had already begun.
During yesterday's briefing on marketing changes for non-steroidal anti-inflammatory drugs (NSAIDs), the FDA said it would "carefully review any proposal from Merck" for resuming the marketing of Vioxx and would likely discuss the review with the new FDA Drug Safety Oversight Board and an Advisory Committee before making a final decision.
In a statement yesterday, Merck added that while it respects the FDA's position on use of NSAIDs and cardiac trouble in some patients, it also believes there is still a patient need for the drugs.
Share this article:

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.